KDR and breast cancer: In addition, Tie2 and VEGFR pathways play varying roles in TEM angiogenic and lymphangiogenic activities across breast cancer (BC) patients; nevertheless, a combination of Tie2 and VEGFR kinase inhibitors inhibited these activities and overcame inter-patient variability [140].